Q4 2025 INmune Bio Inc Earnings Call Transcript
Key Points
- INmune Bio Inc (INMB) completed the MINDFuL Alzheimer's trial and advanced CORDStrom towards registration, positioning their platform programs for the next stage of development.
- The CORDStrom program showed promising results in Recessive Dystrophic Epidermolysis Bullosa (RDEB) with clinical meaningful wound healing, reductions in itch, and improvements in quality of life.
- INmune Bio Inc (INMB) is preparing regulatory submissions for CORDStrom in the UK and the United States, with plans to file the MAA in the UK by the end of summer 2026.
- The company completed its Phase 2 trial in metastatic castration-resistant prostate cancer ahead of schedule and under budget, meeting its primary endpoint and two of its three secondary endpoints.
- INmune Bio Inc (INMB) has a clear strategy for advancing multiple differentiated platforms in parallel, creating meaningful opportunities for value creation.
- The net loss attributable to common stockholders for the year-ended December 31, 2025, was approximately $45.9 million, an increase from the previous year.
- The company recorded a full impairment of its intangible asset of $16.5 million in 2025 following the release of the Phase 2 results of the Alzheimer's trial, which did not meet the clinical endpoint.
- Research and development expenses decreased due to lower expenses in connection with the Alzheimer's trial, indicating potential challenges in funding or prioritizing projects.
- The company is reliant on securing partnerships and funding to support the late-stage development of XPro, which may pose a risk if not achieved.
- There are regulatory challenges, such as the need to create new master seed stock for the FDA submission due to the sensitivity of using UK donor materials in the US.
Greetings and welcome to the INmune Bio's 2025 fourth-quarter and year-end earnings call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is now my pleasure to introduce Mr. Daniel Carlson, Head of Investor Relations of INmune Bio. Daniel.
Thank you, Chloe, and good afternoon, everyone. We thank you for joining us on the call for INmune Bio's 2025 fourth-quarter and year-end financial results.
Presenting on today's call are David Moss, CEO and Co-Founder of INmune Bio; Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio; Dr. CJ Barnum, Head of Neuroscience; and Corey Ellspermann, INmune Bio's CFO.
Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
